Financial Review: Titan Medical (NASDAQ:TMDIF) and Avinger (NASDAQ:AVGR)

Titan Medical (NASDAQ:TMDIFGet Free Report) and Avinger (NASDAQ:AVGRGet Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, valuation, analyst recommendations and institutional ownership.

Risk & Volatility

Titan Medical has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500. Comparatively, Avinger has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500.

Earnings & Valuation

This table compares Titan Medical and Avinger”s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Titan Medical $17.63 million 2.59 $6.95 million $0.05 8.00
Avinger $7.26 million 0.66 -$18.32 million ($11.06) -0.13

Titan Medical has higher revenue and earnings than Avinger. Avinger is trading at a lower price-to-earnings ratio than Titan Medical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Titan Medical and Avinger’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Titan Medical N/A -82.31% -51.47%
Avinger -261.06% -5,527.11% -123.25%

Institutional and Insider Ownership

0.0% of Titan Medical shares are owned by institutional investors. Comparatively, 18.3% of Avinger shares are owned by institutional investors. 0.0% of Titan Medical shares are owned by insiders. Comparatively, 43.7% of Avinger shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Titan Medical and Avinger, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Titan Medical 0 0 0 0 0.00
Avinger 0 0 1 0 3.00

Avinger has a consensus target price of $5.00, indicating a potential upside of 244.83%. Given Avinger’s stronger consensus rating and higher possible upside, analysts clearly believe Avinger is more favorable than Titan Medical.

Summary

Titan Medical beats Avinger on 8 of the 14 factors compared between the two stocks.

About Titan Medical

(Get Free Report)

Titan Medical Inc. operates as a medical technology company. It focuses on the development and licensing of robotic assisted surgical technologies. The company is headquartered in Toronto, Canada.

About Avinger

(Get Free Report)

Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. Its lumivascular products comprise Lightbox imaging consoles; the Ocelot and Tigereye family of devices, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. The company is also developing IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. The company was incorporated in 2007 and is based in Redwood City, California.

Receive News & Ratings for Titan Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Medical and related companies with MarketBeat.com's FREE daily email newsletter.